top of page
< Back

Bevacizumab


Mechanism of action:

Bevacizumab is a recombinant monoclonal antibody. Bevacizumab specifically binds to free VEGF-A, preventing its interaction with VEGFR-1 and VEGFR-2, thereby inhibiting endothelial cell activation and angiogenesis, and consequently affecting vascular generation-related processes within the tumor microenvironment.

Reference(s):

1. Velcheti V et al. (2006). The proportion of patients with metastatic non-small cell lung cancer potentially eligible for treatment with bevacizumab: a single institutional survey. J Thorac Oncol. 


2. Rosen LS et al. (2017). Bevacizumab in colorectal cancer: current role in treatment and the potential of biosimilars. Target Oncol. 


3. Han K et al. (2016). Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer Chemother Pharmacol.

bottom of page